BASF Plans to Ramp Up R&D Spending

BASF plans to “ramp up” spending to develop diagnostic and prognostic test products designed by its Metanomics Health (Berlin) human health biotechnology business, said Peter Oakley, BASF board member/agricultural products and fine chemicals, at a briefing in Berlin last month. Metanomics Health is developing novel diagnostic tests including products to predict the onset of certain diseases such as diabetes, potentially enabling physicians to prevent their onset. BASF says it has established proof of concept for the tests. Metanomics Health, to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers